Protocols

Important Disclaimer: The information below describes research protocols from published studies and is not personalized medical advice. LL-37 is not an approved therapeutic agent for clinical use outside of research settings. Any therapeutic use should only occur under proper medical supervision and appropriate regulatory oversight.

The available evidence provides very limited information about specific dosing and administration protocols for LL-37. The peptide appears primarily in research contexts rather than as a direct therapeutic intervention.

Research Context

The published literature focuses predominantly on LL-37 as an endogenous antimicrobial peptide that is measured as a biomarker rather than administered as therapy. Several studies examine LL-37 levels in various disease states including periodontal disease, tuberculosis, and inflammatory conditions, but these are observational studies measuring naturally occurring peptide levels rather than intervention trials.

Indirect Approaches

The clinical trials identified focus on vitamin D supplementation as a means to potentially influence endogenous LL-37 production, since vitamin D is known to regulate cathelicidin (LL-37) expression. However, specific protocols for direct LL-37 administration are not detailed in the available evidence.

One completed study (NCT03923218) examined "Effects of Smoking and Vitamin D3 on the Levels of Human Cathelicidin Peptide LL-37," but the specific vitamin D3 dosing protocols used are not provided in the available information.

Evidence Limitations

The current evidence base does not contain sufficient detail about standardized dosing regimens, administration routes, treatment durations, or safety monitoring protocols for direct LL-37 therapy. Most research appears to focus on the peptide's biological functions and measurement as a biomarker rather than its therapeutic administration.

Further research would be needed to establish appropriate clinical protocols for any potential therapeutic use of LL-37.

LL-37

Member access required